Switzerland·Stock·SIX (Switzerland)Galderma Group AG (GALD.SW)
Health Care · Drug Manufacturers - Specialty & Generic · Europe
Price in CHF, last 5 years
- Last price
- CHF 187.30 (Oct 22, 2026)
- 1-year return
- +37.7%
- 3-year annual return
- —
- 5-year annual return
- —
- 1-year volatility
- 29.3%
- Max drawdown (5Y)
- -38.8%
- Market cap (approx.)
- US$52.9B
- History available
- since Mar 21, 2024
About Galderma Group AG
Galderma Group AG (GALD.SW) is a stock from Switzerland that trades on SIX (Switzerland) in CHF. It operates in the health care sector, Drug Manufacturers - Specialty & Generic industry. It's part of the SMI.
Over the last year its price rose 37.7% in CHF, with annual volatility of 29%: a moderately volatile asset. Its worst drop over the last five years was 38.8% from a peak.
If your currency isn't the CHF, your real return will also depend on the exchange rate. In the optimizer you can choose your currency (USD, EUR, MXN, BRL, CLP, COP, PEN or ARS) and the calculation includes that currency risk.
How does it fit into a portfolio? What matters is not just its risk on its own, but how much it moves together with your other assets. Add it to your list and the optimizer will show you what weight the model would give it and why.
Other health care assets in Europe
| Asset | 1 year | 1Y return | Volatility | Market cap | |
|---|---|---|---|---|---|
Roche Holding AGROP.SW · Stock · Health Care | +43.5% | 24% | US$378.1B | ||
Novartis AGNOVN.SW · Stock · Health Care | +26.6% | 23% | US$298.0B | ||
 AstraZeneca PLCAZN.L · Stock · Health Care | +2.8% | 27% | US$266.9B | ||
GSK plcGSK.L · Stock · Health Care | +14.9% | 25% | US$101.6B | ||
 SanofiSAN.PA · Stock · Health Care | -9.7% | 22% | US$99.9B | ||
EssilorLuxottica Société anonymeEL.PA · Stock · Health Care | -42.3% | 33% | US$90.1B | ||
 argenx SEARGX.BR · Stock · Health Care | +12.2% | 40% | US$56.1B | ||
Lonza Group AGLONN.SW · Stock · Health Care | +13.6% | 23% | US$53.4B |
Disclaimer: Educational and simulation tool. It is not investment advice or a personalized recommendation. Past performance does not guarantee future results. Data for educational purposes; it may be delayed or contain errors.